Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59:478–90.
Graddis TJ, Remmele Jr RL, McGrew JT. Designing proteins that work using recombinant technologies. Curr Pharm Biotechnol. 2002;3:285–97.
Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315–29.
Sola RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci. 2009;98:1223–45.
Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol. 2008;141:287–97.
Dummer R, Mangana J. Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics. 2009;3:169–82.
Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs. 2010;24:9–21.
Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L, et al. Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnol. 2008;8:65.
Adolf GR, Kalsner I, Ahorn H, Maurer-Fogy I, Cantell K. Natural human interferon-alpha 2 is O-glycosylated. Biochem J. 1991;276(Pt 2):511–8.
Johnson WC. Analyzing protein circular dichroism spectra for accurate secondary structures. Proteins. 1999;35:307–12.
Greenfield NJ. Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nat Protoc. 2006;1:2527–35.
Larocque L, Blui A, Xu R, Diress A, Wang J, Lin R, et al. Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotech. 2011;in press.
Johnston MJ, Nemr K, Hefford MA. Influence of bovine serum albumin on the secondary structure of interferon alpha 2b as determined by far UV circular dichroism spectropolarimetry. Biologicals. 2010;38:314–20.
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544–75.
Philo JS, Arakawa T. Mechanisms of protein aggregation. Curr Pharm Biotechnol. 2009;10:348–51.
Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. Rational design and engineering of therapeutic proteins. Drug Discov Today. 2003;8:212–21.
Worn A, Auf der Maur A, Escher D, Honegger A, Barberis A, Pluckthun A. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J Biol Chem. 2000;275:2795–803.
Di NL, Whitson LJ, Cao X, Hart PJ, Levine RL. Proteasomal degradation of mutant superoxide dismutases linked to amyotrophic lateral sclerosis. J Biol Chem. 2005;280:39907–13.
Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 1999;59:5758–67.
Cha SS, Kim JS, Cho HS, Shin NK, Jeong W, Shin HC, et al. High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity. J Biol Chem. 1998;273:2153–60.
Durocher Y, Butler M. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol. 2009;20:700–7.
Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, et al. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem. 1991;266:23022–6.
Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res. 1998;15:641–9.
Yesilyurt BT, Gielens C, Meersman F. Thermal stability of homologous functional units of Helix pomatia hemocyanin does not correlate with carbohydrate content. FEBS J. 2008;275:3625–32.
Spiriti J, Bogani F, van der Vaart A, Ghirlanda G. Modulation of protein stability by O-glycosylation in a designed Gc-MAF analog. Biophys Chem. 2008;134:157–67.
Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie. 2008;90:437–49.
Ceaglio N, Etcheverrigaray M, Conradt HS, Grammel N, Kratje R, Oggero M. Highly glycosylated human alpha interferon: an insight into a new therapeutic candidate. J Biotechnol. 2010;146:74–83.
Silva MM, Gaines-Das RE, Jones C, Robinson CJ. Biological activity of EDQM CRS for Interferon alfa-2a and Interferon alfa-2b—assessment in two in vitro bioassays. Pharmeur Bio. 2007;2007:1–6.
Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol. 1997;274:661–75.
Simons B, Scholl D, Cyr T, Hefford MA. Effects of increased loop flexibility on the structure and stability of a de novo designed helical protein. Protein Pept Lett. 2001;8:89–96.
Kumaran J, Wei L, Kotra LP, Fish EN. A structural basis for interferon-alpha-receptor interactions. FASEB J. 2007;21:3288–96.